Loading organizations...
Based in San Diego, California, Abterra Biosciences operates as a contract research organization that provides computational and experimental technologies for mapping antibody responses and discovering new therapeutics. The company utilizes next-generation sequencing, mass spectrometry, and machine learning to analyze immune repertoires through proprietary software platforms like Reptor, Valens, and Alicanto. Operating with a small team that included six employees in 2020, the business generates revenue through fee-for-service research, software licensing, and collaborative partnerships. The enterprise has secured multiple federal research grants, including a $1.8 million Small Business Innovation Research award from the National Institutes of Health in September 2024. Originally established as a spin-out from the University of California San Diego under the name Digital Proteomics, the firm was founded in 2009 by Pavel Pevzner, Vineet Bafna, Natalie Castellana, Stefano Bonissone, and Anand Patel.
Abterra Biosciences has raised $225.1M across 1 funding round.
Abterra Biosciences has raised $225.1M in total across 1 funding round.
Abterra Biosciences has raised $225.1M across 1 funding round. Most recently, it raised $225.1M Other Equity / Seed in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 10, 2021 | $225.1M Venture Round | — | SAN Diego Angel Conference, Seattle Angel Conference | Announced |
Abterra Biosciences has raised $225.1M in total across 1 funding round.
Abterra Biosciences's investors include San Diego Angel Conference, Seattle Angel Conference.
